PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol

Pediatric Blood and Cancer

Volumn 62, Issue 3, 2015, Pages 427-433

  Henriksen, Louise Tram ^a   Harila Saari, Arja ^b   Ruud, Ellen ^c   Abrahamsson, Jonas ^d   Pruunsild, Kaie ^e   Vaitkeviciene, Goda ^f   Jónsson, Ólafur Gísli ^g   Schmiegelow, Kjeld ^h,i   Heyman, Mats ^b   Schrøder, Henrik ^a   Albertsen, Birgitte Klug ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b KAROLINSKA INSTITUTE   (Sweden)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^e Tallinn Children Hospital   (Estonia)

^f VILNIUS UNIVERSITY   (Lithuania)

^g LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^h Mental Health Center Glostrup   (Denmark)

ⁱ UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Acute lymphoblastic leukemia; Allergy; Asparaginase; Children

Indexed keywords

ASPARAGINASE; ASPARAGINASE MACROGOL; ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLERGIC REACTION; ANGIONEUROTIC EDEMA; ARTICLE; BRONCHOSPASM; CHILD; CHILDHOOD CANCER; CLINICAL FEATURE; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FEMALE; FLUSHING; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PRIORITY JOURNAL; RASH; RISK ASSESSMENT; SYSTEMIC ANAPHYLAXIS; TREATMENT DURATION; URTICARIA; ADULT; ANAPHYLAXIS; CHEMICALLY INDUCED; CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; INFANT; MULTICENTER STUDY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ADOLESCENT; ADULT; ANAPHYLAXIS; ANTINEOPLASTIC AGENTS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALE; POLYETHYLENE GLYCOLS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK FACTORS;

EID: 84921326710     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25319     Document Type: Article

References (27)

1. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Arkin S, Declerck L, Cohen HJ, Sallan SE. Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01. Blood 2001: 97:1211-1218.
2. Wang B, Relling MV, Storm MC, Woo MH, Ribeiro R, Pui CH, Hak LJ. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia 2003: 17:1583-1588.
3. Woo MH, Hak LJ, Storm MC, Sandlund JT, Ribeiro RC, Rivera GK, Rubnitz JE, Harrison PL, Wang B, Evans WE, Pui CH, Relling MV. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2000: 18:1525-1532.
4. Evans WE, Tsiatis A, Rivera G, Murphy SB, Dahl GV, Denison M, Crom WR, Barker LF, Mauer AM. Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer 1982: 49:1378-1383.
5. Avramis VI, Sencer S, Periclou AP, Sather H, Bostrom BC, Cohen LJ, Ettinger AG, Ettinger LJ, Franklin J, Gaynon PS, Hilden JM, Lange B, Majlessipour F, Mathew P, Needle M, Neglia J, Reaman G, Holcenberg JS, Stork L. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2002: 99:1986-1994.
6. Muller HJ, Beier R, Loning L, Blutters-Sawatzki R, Dorffel W, Maass E, Muller-Weihrich S, Scheel-Walter HG, Scherer F, Stahnke K, Schrappe M, Horn A, Lumkemann K, Boos J. Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. Br J Haematol 2001: 114:794-799.
7. Wacker P, Land VJ, Camitta BM, Kurtzberg J, Pullen J, Harris MB, Shuster JJ. Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: A Children's Oncology Group Study. J Pediatr Hematol Oncol 2007: 29:627-632.
8. Woo MH, Hak LJ, Storm MC, Evans WE, Sandlund JT, Rivera GK, Wang B, Pui CH, Relling MV. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 1998: 12:1527-1533.
9. Narta UK, Kanwar SS, Azmi W. Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Crit Rev Oncol Hematol 2007: 61:208-221.
10. Sirvent N, Suciu S, Rialland X, Millot F, Benoit Y, Plantaz D, Ferster A, Robert A, Lutz P, Nelken B, Plouvier E, Norton L, Bertrand Y, Otten J. Prognostic significance of the initial cerebro-spinal fluid (CSF) involvement of children with acute lymphoblastic leukaemia (ALL) treated without cranial irradiation: Results of European Organization for Research and Treatment of Cancer (EORTC) Children Leukemia Group study 58881. Eur J Cancer 2011: 47:239-247.
11. Silverman LB, Stevenson KE, O'Brien JE, Asselin BL, Barr RD, Clavell L, Cole PD, Kelly KM, Laverdiere C, Michon B, Schorin MA, Schwartz CL, O'Holleran EW, Neuberg DS, Cohen HJ, Sallan SE. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia 2010: 24:320-334.
12. Moghrabi A, Levy DE, Asselin B, Barr R, Clavell L, Hurwitz C, Samson Y, Schorin M, Dalton VK, Lipshultz SE, Neuberg DS, Gelber RD, Cohen HJ, Sallan SE, Silverman LB. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007: 109:896-904.
13. Vrooman LM, Supko JG, Neuberg DS, Asselin BL, Athale UH, Clavell L, Kelly KM, Laverdiere C, Michon B, Schorin M, Cohen HJ, Sallan SE, Silverman LB. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2010: 54:199-205.
14. Liu C, Kawedia JD, Cheng C, Pei D, Fernandez CA, Cai X, Crews KR, Kaste SC, Panetta JC, Bowman WP, Jeha S, Sandlund JT, Evans WE, Pui CH, Relling MV. Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia 2012: 26:2303-2309.
15. Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A, Goekbuget N, Schrappe M, Pui CH. L-asparaginase treatment in acute lymphoblastic leukemia: A focus on Erwinia asparaginase. Cancer 2011: 117:238-249.
16. Toft N, Birgens H, Abrahamsson J, Bernell P, Griskevicius L, Hallbook H, Heyman M, Holm MS, Hulegardh E, Klausen TW, Marquart HV, Jonsson OG, Nielsen OJ, Quist-Paulsen P, Taskinen M, Vaitkeviciene G, Vettenranta K, Asberg A, Schmiegelow K. Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol. Eur J Haematol 2013: 90:404-412.
17. Frandsen TL, Heyman M, Abrahamsson J, Vettenranta K, Sberg A, Vaitkeviciene G, Pruunsild K, Toft N, Birgens H, Hallbook H, Quist-Paulsen P, Griskevicius L, Helt L, Hansen BV, Schmiegelow K. Complying with the European Clinical Trials directive while surviving the administrative pressure - An alternative approach to toxicity registration in a cancer trial. Eur J Cancer 2014: 50:251-259.
18. Raja RA, Schmiegelow K, Albertsen BK, Prunsild K, Zeller B, Vaitkeviciene G, Abrahamsson J, Heyman M, Taskinen M, Harila-Saari A, Kanerva J, Frandsen TL. Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol. Br J Haematol 2014: 165:126-133.
19. Albertsen BK, Hasle H, Clausen N, Schroder H, Jakobsen P. Pain intensity and bioavailability of intramuscular asparaginase and a local anesthetic: A double-blinded study. Pediatr Blood Cancer 2005: 44:255-258.
20. Pidaparti M, Bostrom B. Comparison of allergic reactions to pegasparaginase given intravenously versus intramuscularly. Pediatr Blood Cancer 2012: 59:436-439.
21. Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK, Williams H. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006: 368:733-743.
22. Mallol J, Crane J, von ME, Odhiambo J, Keil U, Stewart A. The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three: A global synthesis. Allergol Immunopathol (Madr) 2013: 41:73-85.
23. Harmatz A. Local anesthetics: uses and toxicities. Surg Clin North Am 2009: 89:587-598.
24. Albertsen BK, Schroder H, Jakobsen P, Avramis VI, Muller HJ, Schmiegelow K, Carlsen NT. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase. Med Pediatr Oncol 2002: 38:310-316.
25. Willer A, Gerss J, Konig T, Franke D, Kuhnel HJ, Henze G, von SA, Moricke A, Schrappe M, Boos J, Lanvers-Kaminsky C. Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: A retrospective analysis within the ALL-BFM trials. Blood 2011: 118:5774-5782.
26. Panosyan EH, Seibel NL, Martin-Aragon S, Gaynon PS, Avramis IA, Sather H, Franklin J, Nachman J, Ettinger LJ, La M, Steinherz P, Cohen LJ, Siegel SE, Avramis VI. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol 2004: 26:217-226.
27. Tong WH, Pieters R, Kaspers GJ, Te Loo DM, Bierings MB, van den Bos C, Kollen WJ, Hop WC, Lanvers-Kaminsky C, Relling MV, Tissing WJ, van der Sluis IM. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood 2014: 123:2026-2033.